66981-77-9

Basic information

• Product Name: Tianeptine Ethyl Ester
• Synonyms: Tianeptine Ethyl Ester;FEFUFMZSNHPQDX-UHFFFAOYSA-N
• CAS NO: 66981-77-9
• Molecular Formula: C23H29ClN2O4S
• Molecular Weight: 465.00536
• Mol File: 66981-77-9.mol

Chemical Properties

• Boiling Point: 573.3±60.0 °C(Predicted)
• Appearance: /
• Density: 1.30±0.1 g/cm3(Predicted)
• Storage Temp.: Refrigerator, under inert atmosphere
• Solubility: Chloroform (Slightly), Methanol (Slightly)
• PKA: 7.44±0.20(Predicted)
• CAS DataBase Reference: Tianeptine Ethyl Ester(CAS DataBase Reference)
• NIST Chemistry Reference: Tianeptine Ethyl Ester(66981-77-9)
• EPA Substance Registry System: Tianeptine Ethyl Ester(66981-77-9)

Safety Data

• Hazardous Substances Data: 66981-77-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Tianeptine Ethyl Ester is used as an impurity in the production of Tianeptine, which is a tricyclic compound with various therapeutic properties. It is utilized for its psychostimulant effects, as well as its ability to treat ulcers and prevent nausea and vomiting.

Upstream product

• 191172-75-5 tianeptine 
• 64-17-5 ethanol 
• 26638-53-9 8-chloro-10,10-dioxo-11-methyl-5,11-dihydrodibenzo<1,2>thiazepin-5-one 
• 1117-66-4 7-aminoheptanoic acid ethyl ester 
• 26723-60-4 5-hydroxy-8-chloro-10,10-dioxo-11-methyl-5,11-dihydrodibenzo<1,2>thiazepine 
• 26638-66-4 5,8-dichloro-10,10-dioxo-11-methyl-5,11-dihydrodibenzo<1,2>thiazepine 
• 29840-65-1 7-aminoheptanoic acid ethyl ester hydrochloride 

Relevant articles and documents

A process for preparing 3,11-Dichloro-6-methyl -6,11-dihydrodibenzo[c,f][1,2]thiazepine 5,5-dioxide

The present invention relates to a method for preparing 3,11-dichloro-6-methyl-6,11-dihydrodibenzo[c,f][1,2]thiazepine 5,5-dioxide. More particularly, the present invention relates to a method for preparing high-purity 3,11-dichloro-6-methyl-6,11-dihydrodibenzo[c,f][1,2]thiazepine 5,5-dioxide at a high yield under safe atmosphere through a quantitative reaction without introduction of an excessive amount of hydrogen chloride gas from the outside by substituting the hydroxyl group of 3-chloro-6-methyl-6,11-dihydrodibenzo[c,f][1,2]thiazepine-11-ol 5,5-dioxide as a starting material with a chloride group by means of hydrogen chloride gas generated in situ under the environment of acetyl chloride and the same equivalent of alcohol.

Synthesis method of tianeptine sodium

The invention relates to a synthesis process of a drug tianeptine sodium, particularly to a method for synthesizing tianeptine sodium by using 3-chloro-6-methyldibenzo[c,f][1,2]thiazepine-11(6H)-keto-5,5-dioxide as a starting material through Schiff base forming with an amine, reducing, hydrolyzing, and freeze-drying and salt forming. According to the invention, the method is stable in starting material, easy to purchase and simple in process; and the synthesis route is mild in overall reaction condition, simple in experimental operation and easy to realize industrial production.

Tianeptine esters derivatives: A study of protein-drug interaction performed by fluorescence quenching and molecular docking

The nature of binding between bovine serum albumin (BSA) and the antidepressant tianeptine and a new series of esters derivatives were studied in this paper. The interactions with BSA were investigated by UV-Vis and fluorescence spectroscopy at three different temperatures. The fluorescence quenching experiments showed that BSA interactions with tianeptine could be dynamic while to its esters a static mechanism was observed. The results showed that tianeptine quenches the intrinsic fluorescence of BSA more efficiently than its esters due to the presence of the free acid portion. The number of binding sites determined by fluorescence spectroscopy is approximately equal to 1 indicating that there is one binding site between BSA tianeptine esters, but the presence of a second interaction site for tianeptine at higher temperatures could be not ruled out. Molecular docking calculations point out a strong affinity of tianeptine and its esters to the site IIA of protein, supporting the hypothesis of a static quenching mechanism.

A NEW CLASS OF MU-OPIOID RECEPTOR AGONISTS

The present invention provides a compound having the structure (I) or a pharmaceutically acceptable salt or ester thereof.